Rheumatology

Updated EULAR RA Treatment Recommendations Address Patient Concerns, Recent Developments

February 9th 2020

By Maggie L. Shaw

Updated guidelines from the European League Against Rheumatism (EULAR), based on new evidence and a review of the literature from 2016 to 2018, address recommendations on the use of disease-modifying antirheumatic drugs and glucocorticoids to treat patients with rheumatoid arthritis (RA). Included is guidance on mono- and combination therapies, treatment strategies, and tapering treatment.

Nonprofit Payer Says It Saved $1.7 Million Through Use of Infliximab Biosimilars

January 22nd 2020

By The Center for Biosimilars Staff

Article

Health New England says it achieved 93% utilization by requiring prior authorization.

Celltrion Amps Up Its Biosimilar Launch Schedule

January 22nd 2020

By Tony Hagen

Article

The company's announcement of an aggressive launch calendar at the JP Morgan Healthcare Conference in San Francisco last week was followed by Celltrion’s announcement this week that it plans to open a large biologics manufacturing plant in Wuhan, China.

ICER Releases Final Report on JAK Inhibitors for Rheumatoid Arthritis

January 13th 2020

By Deana Ferreri, PhD

Article

The final report includes voting results from a December 2019 meeting of one of ICER’s independent evidence appraisal panels, the California Technology Assessment Forum (CTAF), plus policy recommendations from an expert roundtable.

Bio-Thera Solutions' Biosimilar Adalimumab Launches in China

January 10th 2020

By The Center for Biosimilars Staff

Article

It is the first adalimumab biosimilar approved by the China National Medical Products Administration.

Another European Study Finds SB4 Tolerated by Most Patients

January 10th 2020

By Peter Page

Article

The study follows others that have found that SB4 works well for the majority of patients who switched from the originator etanercept, Enbrel.

2 Studies Report on Biosimilar Adalimumab Hulio

January 9th 2020

By Peter Page

Article

Two studies recently reported on Hulio, the adalimumab biosimilar marketed and developed by Mylan and its partner Fujifilm Kyowa Kirin Biologics.

IVI Updates RA Value Assessment Model to Include Biosimilars, Sarilumab, JAK Inhibitors

January 9th 2020

By The Center for Biosimilars Staff

Article

The Innovation and Value Initiative (IVI) has updated its existing prototype economic model examining value among rheumatoid arthritis (RA) therapies to include biosimilars.

FDA Touts Biosimilar Approvals in Annual CDER Report

January 8th 2020

By The Center for Biosimilars Staff

Article

In 2019 the FDA approved 48 novel drugs and 10 biosimilars, according to the Center for Drug Evaluation and Research (CDER).

Gilead Submits JAK Inhibitor, Filgotinib, Under Priority Review for Rheumatoid Arthritis

January 2nd 2020

By The Center for Biosimilars Staff

Article

Last month, Gilead Sciences submitted a New Drug Application (NDA) to the FDA for filgotinib under the priority review process. Filgotinib is a Janus kinase (JAK) inhibitor aimed at moderate-to-severe rheumatoid arthritis (RA).